The Food and Drug Administration has told STAT that it is developing a plan for how to regulate medical devices that use generative AI. The publicly available portion of the STAT report states the agency is actively considering how to approach regulation of this class of technology in medical products.
The reporting identifies the Digital Health Center of Excellence at the FDA as the focal office for the comments and frames the announcement as part of the agency’s broader engagement with digital health regulation.
Rick Abramson, director of the FDA’s Digital Health Center of Excellence, is quoted in the STAT piece saying the FDA will eventually release documents that spell out agency policies on generative AI. Abramson described the agency’s goal as issuing “formal policy guidance.”
The STAT excerpt stresses that the agency recognizes demand from industry and other stakeholders for clarity about how generative AI in medical devices will be regulated. Abramson’s remarks are presented as a direct response to an ecosystem that is “expecting clarity.”
According to the STAT reporting, Abramson indicated that stakeholders can expect more than a single overarching document. He said the FDA aims to provide both broad guidance addressing generative AI overall, and additional, more narrowly constructed guidance aimed at particular generative AI topics of “special interest or special complexity.”
The publicly available article does not specify which topics would receive specialty guidance, nor does it enumerate the areas of interest or complexity that the FDA plans to prioritize.
The source includes Abramson’s statement: “Our goal is formal policy guidance,” and that the agency aims to provide clarity to an ecosystem that is awaiting it. The article also reports Abramson’s expectation that guidance will include both broad and more narrowly focused documents.
No further direct quotes or explanatory detail from Abramson beyond those points are included in the accessible portion of the STAT piece.
The STAT article is presented as a STAT+ exclusive; the publicly viewable excerpt reports the FDA’s intention and Abramson’s high-level comments. However, several important operational details were not provided in the accessible content:
The source did not report any timelines or target dates for publication of the promised guidances.
No draft text, proposed regulatory language, or specific policy elements were included in the available excerpt.
The article did not publish which specific medical device categories, clinical contexts, or generative AI use cases would be covered first or considered highest priority.
There is no description in the accessible text of whether the FDA plans changes to existing device premarket review pathways, postmarket surveillance expectations, or other procedural mechanisms tied to generative AI devices.
The STAT piece did not report stakeholder reactions, examples of models or products of interest, or technical definitions the FDA intends to use for “generative AI.”
These gaps reflect the limited public portion of the source. The STAT article indicates more detailed reporting is available to STAT+ subscribers; those additional details were not present in the excerpt provided.
From the statements reported, the FDA’s publicly stated intent to issue formal guidance signals that regulators are moving toward clarifying expectations for companies developing or deploying generative AI in medical devices. The dual approach—broad guidance plus specialty guidances—suggests the agency plans to address both general principles and specific complex or high-risk use cases.
Because the accessible source does not provide timelines, draft language, or procedural details, stakeholders seeking to plan product development, submissions, or compliance should monitor FDA announcements and the Digital Health Center of Excellence for forthcoming documents.
If users require the full text of the STAT report or the additional reporting that may include timelines, specific topics, or expanded quotations, the article notes that such content is part of STAT+ subscriber material and is not reproduced in the publicly available excerpt.
All statements in this summary are drawn from the publicly accessible portion of the STAT News article. Where the article withheld further details behind a subscription paywall, this summary notes the absence of that information rather than inferring or inventing specifics about FDA plans, dates, or draft policy content.
For updates, readers should consult FDA communications from the Digital Health Center of Excellence and the full STAT reporting for any expanded coverage or additional facts when they become publicly available.